Eikon Therapeutics presented updated EIK1001 trial data on October 26, 2026, showing responses among patients with previously untreated stage 4 non-small cell lung cancer who received the investigational drug alongside pembrolizumab and chemotherapy.
Key Takeaways
- The objective response rate was 72.4% in the efficacy-evaluable squamous cohort and 55.6% in the non-squamous cohort.
- Grade 3 or higher treatment-related adverse events occurred in 48.6% of the 72 participants evaluated for safety.
- A separate Phase 2/3 trial is enrolling, with an interim dose-selection analysis expected in the second half of 2027.
EIK1001 trial results by cancer subtype
The open-label TeLuRide-005 study enrolled 72 participants with previously untreated stage 4 non-small cell lung cancer. Of those, 65 were evaluable for efficacy at the October 1, 2026, data cutoff.
Across the evaluable population, the objective response rate was 63.1% and the disease control rate was 89.2%, with median follow-up of 17.2 months. The study evaluated the combination of EIK1001, pembrolizumab and chemotherapy; the reported results do not isolate the effect of EIK1001.
| Item | Details |
|---|---|
| Squamous cohort | 29 efficacy-evaluable participants; 72.4% objective response rate and 100% disease control rate. |
| Squamous follow-up | Median follow-up of 12.7 months and median response duration of 12.9 months. |
| Non-squamous cohort | 36 efficacy-evaluable participants; 55.6% objective response rate and 80.6% disease control rate. |
| Non-squamous follow-up | Median follow-up of 17.9 months and median response duration of 11.2 months. |
Safety and treatment schedule
At the July 13 safety cutoff, treatment-related adverse events led to discontinuation in 6.9% of participants. The most common events of grade 3 or higher were neutropenia, at 30.6%, and anemia and thrombocytopenia, each at 9.7%. No treatment-related adverse events led to death.
Eikon said the safety profile supported outpatient administration during the ongoing trial. Participants initially received intravenous EIK1001 weekly; after eight cycles, administration was reduced to once every three weeks.
Phase 2/3 study is enrolling
Eikon is also conducting TeLuRide-008, an adaptive Phase 2/3 trial of the same combination in previously untreated patients with stage 4 squamous or non-squamous non-small cell lung cancer. The company expects an interim analysis to select a dose for the remainder of the trial in the second half of 2027.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
Comments
Be respectful. No spam, impersonation or private credentials. Ordinary posts and comments appear immediately; suspicious links are held for review.
Please wait…